



(51) International Patent Classification:

A61K 31/16 (2006.01) *C07C 1/00* (2006.01)
A61K 9/00 (2006.01) *A61K 9/28* (2006.01)
A61P 43/00 (2006.01) *A61K 47/40* (2006.01)

(72) Inventors: **LEROUX, Jean-Christophe**; In der Sommer-
 au 8, 8053 Zurich (CH). **ILIEVSKI, Filip**; UL. Gjorche
 Petrov no. 120, 1000 Skopje (MK). **EVSTAFEVA, Diana**;
 Probusweg 26, 8057 Zurich (CH).

(21) International Application Number:

PCT/IB2022/056066

(22) International Filing Date:

29 June 2022 (29.06.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:



21182587.2 29 June 2021 (29.06.2021) EP

(71) Applicant: **ETH ZURICH [CH/CH]**; Raemistrasse 101/
 ETH transfer, 8092 Zurich (CH).

(81) Designated States (unless otherwise indicated, for every
 kind of national protection available): AE, AG, AL, AM,
 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
 CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
 HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH,
 KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
 MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
 NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
 RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
 TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
 ZW.

(54) Title: UNSATURATED HYDROXAMIC ACID DERIVATIVES AND THEIR USE FOR THE TREATMENT AND PREVEN-
 TION OF AN AMMONIA-ASSOCIATED DISEASE OR DISORDER

FIG. 7



(57) Abstract: The present disclosure provides an enteral or urinary pharmaceutical formulation comprising (A) a compound of formula I, (I), wherein R_1 is a C1-C3 alkyl; X is $-\text{C}(\text{R}_2)(\text{R}_3)-\text{C}(\text{R}_4)(\text{R}_5)-$ or $-\text{C}\equiv\text{C}-$, wherein R_2 , R_3 , R_4 , and R_5 are each independently H or methyl; Y is $-\text{CH}=\text{CH}-\text{CH}_2-$, $-\text{CH}_2-\text{CH}=\text{CH}-$, $-\text{C}\equiv\text{C}-\text{CH}_2-$, $-\text{CH}_2-\text{C}\equiv\text{C}-$; or $-\text{C}(\text{R}_7)(\text{R}_8)-\text{C}(\text{R}_9)(\text{R}_{10})-\text{C}(\text{R}_{11})(\text{R}_{12})-$, wherein R_7 , R_8 , R_9 , R_{10} , R_{11} and R_{12} , are each independently H or methyl; provided that (1) when X is $-\text{C}\equiv\text{C}-$, Y is $-\text{C}(\text{R}_7)(\text{R}_8)-\text{C}(\text{R}_9)(\text{R}_{10})-\text{C}(\text{R}_{11})(\text{R}_{12})-$ and that (2) when Y is not $-\text{C}(\text{R}_7)(\text{R}_8)-\text{C}(\text{R}_9)(\text{R}_{10})-\text{C}(\text{R}_{11})(\text{R}_{12})-$, X is $-\text{C}(\text{R}_2)(\text{R}_3)-\text{C}(\text{R}_4)(\text{R}_5)-$; and R_6 is H or CH_3 , or a stereoisomer or a mixture thereof, or a pharmaceutically acceptable salt, ester or solvate thereof; and (B) (a) at least one pharmaceutically acceptable

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

excipient; or (b) at least one other therapeutic agent; or (c) a combination of (a) and (b); and a use thereof for the treatment or prevention of an ammonia-associated disease or disorder, or a symptom thereof.